Immunome, Inc.
IMNM
$7.91
$0.7410.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -70.38% | -30.39% | 72.10% | -39.79% | -2,031.97% |
| Total Depreciation and Amortization | 4.20% | -15.16% | 155.89% | 2.33% | 54.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 219.07% | 10.21% | -91.91% | 37.10% | 5,754.49% |
| Change in Net Operating Assets | 136.39% | -21.92% | -36.11% | 156.59% | -35.44% |
| Cash from Operations | -23.10% | -46.03% | -109.46% | 36.02% | -102.68% |
| Capital Expenditure | 97.11% | -1,931.78% | -8.32% | -520.06% | -869.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 200.00% | -478.04% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -84.48% | 162.69% | -- | -- | -- |
| Cash from Investing | -59.51% | 129.50% | -119.41% | -24.10% | -83,238.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,924.56% | -56.23% | -99.50% | 62,864.96% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -96.08% | 56.50% | 96.69% | -125.68% | -9.44% |
| Cash from Financing | 6,485.25% | -56.05% | -99.68% | 295.40% | -8.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.12% | 90.65% | -161.03% | 2,027.94% | -84.61% |